This patient has developed symptomatic WM requiring therapy. Given the severity of this patients symptoms, observation alone would be inappropriate. With anemia and a positive Coombs test in this patient, cold agglutinin syndrome2 or warm antibody-mediated autoimmune hemolytic anemia (AIHA) should be considered. Although fludarabine or other purine analogues are used to treat WM, a patient with a positive baseline Coombs test may be at risk for a life-threatening exacerbation of AIHA following treatment with these agents, as has been described in patients with chronic lymphocytic leukemia.3 Chlorambucil would be a reasonable alternative, as up to 60% of patients with WM respond to this therapy.2 Compared with chlorambucil monotherapy, treatment with multidrug combinations does not improve outcomes and may increase toxicity. Prednisone
1 mg/kg/day would likely be helpful for treatment of AIHA but would not adequately address the patients other symptoms, such as splenomegaly.
- Chlorambucil or another alkylating agent.
2. Johnson SA, Birchall J, Luckie C, et al; Haemato-Oncology Task Force of the British Committee for Standards in Haematology. Guidelines on the management of Waldenström macroglobulinaemia. Br J Haematol 2006;132:683-97.
3. Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol 1998;16:1885-9.
Click here to return to the questions
Seminars in Medical Practice
Hospital Physician Board Review Manuals
Copyright © 2009, Turner White Communications
Updated 6/20/2008 nvf